(Q27919563)

English

RET M918T

genetic variant

MET918THR
M918T
RS74799832

In more languages

default for all languages

No label defined

No description defined

Statements

missense mutation

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/113

human chromosome 10

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/113

43617416

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/113

43617416

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/113

biological variant of

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/113

positive therapeutic predictor for

medical condition treated

Tuberculosis (possibly)

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1365

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

Tuberculosis (possibly)

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/7710

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

negative therapeutic predictor for

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

Tuberculosis (possibly)

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/76

Anti-tumor activity of motesanib in a medullary thyroid cancer model

positive diagnostic predictor for

Tuberculosis (possibly)

determination method or standard

CIViC evidence level B

CIViC 5-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/74

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

negative prognostic predictor for

Tuberculosis (possibly)

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/78

Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.

Identifiers

CIViC variant ID

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/113

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_020975.4:c.2753T>C

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/113

NP_065681.1:p.Met918Thr

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/113

ENST00000355710.3:c.2753T>C

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/113

NC_000010.10:g.43617416T>C

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/113

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27919563&oldid=2014797830"